Chairman & Registrar
Maureen Foulkes(-Hajdu) worked in the Marketing Department of her Father’s very successful scientific instrument manufacturing company (MSE Centrifuges Ltd.) for five years before leaving to change her career path to academia in Montreal, Canada. Initially, she worked for the Dean of Students at Sir George Williams University, and then as Personal Assistant to the Principal of the first English-speaking community college in Quebec, using her fluent French. On returning to the U.K. she worked briefly in the French Department at U.C.L. before landing the job of Registrar of the London Sloan Fellowship Programme at the London Business School (when the Principal was Prof. Sir James Ball, later to become a longstanding Trustee of the Foulkes Foundation). She was a founding Trustee of the Foulkes Foundation when her Father set it up in 1972, and also took on the role of Registrar in 1981; she became Chairman of the Foundation on her Father’s death in 1993. She is dedicated to preserving and enhancing her late Father’s legacy, and is fiercely protective of all the wonderful Fellows the Foundation has had the privilege of supporting over the years. Many of them have made a significant contribution in the fields of science and medicine to the benefit of mankind, and Ernest would certainly have been very proud of the success of his uniquely far-sighted vision.
Georgina graduated from University College London with a BSc in Geography and then moved to France to undertake her Masters in International Business at the Grenoble Graduate Business School. On her return to London, Georgina worked for the French Team at HSBC Investment Bank and then for the Economic Section of the French Embassy. In 2002 she moved to the Telecoms & Technology Division of IIR Conferences (part of the Informa Group) where she worked as a Conference Producer developing, project managing and hosting a number of overseas conferences. In 2007 she was promoted to Conference Director with responsibility for several event portfolios. In 2010, Georgina moved to IQPC, another conference company, where she was responsible for setting up a successful new business in a highly competitive market, and driving it forward to create a reputed market brand that was profitable after just two years. Georgina is a keen saxophonist, playing in quartets and octets, and in the BBC Elstree Concert Band where she is the General Manager, organising all the concerts and overseeing the management of the 45-piece group. She is also past Chairman of the Society of Young Freemen and a Liveryman of the Worshipful Company of Fletchers. Georgina was very honoured to be invited to the 2010 Women of the Year lunch as a Woman of Achievement.
Sir Walter Bodmer
Walter Bodmer studied mathematics at Cambridge University where, having become fascinated with genetics through courses taught by R A Fishers as part of the final year mathematics programme, he did his PhD with Fisher in population genetics. He then went as a Post Doctoral fellow in 1961 to work with Joshua Lederberg at Stanford University and to learn molecular biology. While there, eventually as a member of the Faculty for eight years, he initiated the work with his wife, Julia Bodmer, and with Rose Payne, which contributed to the discovery of the HLA system, and also his long standing involvement with somatic cell genetics. In 1970 Walter Bodmer returned to the UK to take up the chair of genetics at Oxford. In 1979 he left Oxford to become Director of Research at the Imperial Cancer Research Fund Laboratories in London and was appointed the first Director-General of the Fund in 1991. On retirement from the ICRF in 1996, he returned to Oxford University as Principal of Hertford college until 2005, and as head of the ICRF, now CRUK, Cancer and Immunogenetics laboratory at the Weatherall Institute of Molecular medicine where he continues his research. Walter Bodmer was one of the first to suggest the idea of the Human Genome Project and was first a Vice- President, and then the second President of HUGO. He has made major contributions to human population genetics, somatic cell genetics, the development of the HLA system and more recently to cancer genetics, especially as applied to colorectal cancer. Walter Bodmer was elected FRS in 1974, Knighted in 1986 for his contributions to science, is a Foreign Associate of the US National Academy of sciences and is the recipient of more than 30 honorary degrees and memberships and fellowships of scientific and medical societies.
Secretary, Sarasin & Partners
Andrew Hall worked as both a banker and an investment manager for Barclays Bank, before spending ten years with Royal Trust Co. of Canada. After a period as Managing Director of a new company in the Isle of Man he returned as associate director of Royal Trust in London. In 1980 he moved to Aitken Hume Ltd. as investment director. He joined Sarasin Investment Management in 1985 as a director with responsibility for expanding investment services, and was appointed Managing Director in 1989. In March 2002 he was appointed Executive Deputy Chairman and is now partner.
Oscar M Lewisohn, born in 1938 in Copenhagen, was educated at Sortedam Gymnasium, Copenhagen. He joined S.G.Warburg & Co. Ltd., London, in 1962, becoming an executive director in 1969, Deputy Chairman from 1987-1994 and a director of the S.G.Warburg Group plc 1985 – 1995. He is Chairman of Soditic Limited, the London subsidiary of the Soditic Investment Banking group. Mr Lewisohn is a founder member of Cancer Research UK and a trustee of The EORTC Charitable Foundation, Brussels. He is a Trustee of the Edmond Israel Foundation, Luxembourg, a Member of the Council of the Fundación Cultural Coll Bardolet, Valldemossa, Mallorca, and a Governor of the Yehudi Menuhin School, Cobham. He is an Honorary Member of Christ’s College, Cambridge, a Fellow of the Chartered Institute of Bankers, and a Liveryman of The Worshipful Company of International Bankers. Mr Lewisohn is Chairman of the Trustees of The Florestan Trust (The Florestan Trio). Mr Lewisohn is a Knight of the Order of Dannebrog, R1, Denmark.
Professor Sir Alex Markham
University of Leeds & 1980 Foulkes Fellow
Alex Markham completed a Chemistry PhD at the University of Birmingham in 1974 and has undertaken postdoctoral work in Japan, London, Cambridge (UK) and Boston (USA). He entered the commercial sector and had some 15 years’ experience in the pharmaceutical and diagnostics industries in both the UK and the USA, with GD Searle and then ICI Pharmaceuticals (now Astra Zeneca). His commercial experience includes both drug development (Gefitinib) and the worldwide introduction of DNA Fingerprinting for forensic and medico-legal applications. This was recognised by the Queen’s Award for Technological Achievement in 1990. He has made contributions to medical science in various fields. On the basis of his expertise in nucleic acid chemistry, he developed research programmes in medicinal chemistry then molecular biology from the mid ‘70s and was one of the pioneers of molecular genetics research in the UK in the 1980s. For the last 17 years in Leeds, his group has studied autosomal recessive Mendelian disorders in the highly inbred, immigrant communities of West Yorkshire, leading to an understanding of the causes of a variety of inherited neuro-developmental and malignant diseases. He qualified clinically in 1985, training at London and Oxford, and is accredited in pathology and internal medicine. He is the Professor of Medicine in the University of Leeds and directed the Molecular Medicine Institute at St James’s University Hospital. He has undertaken a range of administrative duties at national and international level, including the chairmanship/membership of numerous committees for the Medical Research Council, the Department of Health and the Wellcome Trust, and the International Agency for Research on Cancer (IARC), the Deutsche Krebshilfe, the Singapore Government Agency for Science Technology and Research (A-STAR), the Li Ka Shing Institute of the Chinese University of Hong Kong and the American Association for Cancer Research. A Fellow of the Academy of Medical Sciences and a Board Director of the International Union against Cancer (UICC), he was, until recently, chairman of the National Cancer Research Institute (NCRI). He continues to chair the NCRI Informatics Initiative and the National Cancer Intelligence Network. He has been a founder member of the UK Clinical Research Collaboration (UKCRC) Board and the National Institute of Health Research Advisory Board. He remains a member of the Government’s Cancer Reform Strategy (2007) Advisory Board, and chaired its Clinical Outcomes Group. Alex was Chief Executive of Cancer Research UK for 4 years from 2003-2007. He then returned to academic work at Leeds University but continues as Senior Medical Advisor to CR-UK. He serves on the Department of Health Ministerial/Industry Strategy Group and is Chairman of the Office for Strategic Coordination of Health Research (OSCHR), Translational Medicine Board. He is also the Department of Health Senior Responsible Owner and Board Chairman of the ‘Research Capability Programme’ in NHS “Connecting for Health” and Chairman of the Arthritis Research Campaign Scientific Strategy Committee. He was knighted for ‘Services to Medicine and to Healthcare’ in the Queen’s 2008 New Year Honours List.
Professor Colin Self
University of Newcastle upon Tyne & 1977 Foulkes Fellow
Professor Self’s career started with a Chemistry degree followed by a PhD in Metabolic Biochemistry. He carried out research in Immunology in the USA and in Germany and wrote a book on Immunology. He then took a medical degree at Cambridge University during which his research led to one of the first successful Cambridge biotechnology companies – IQ(Bio) Ltd. After hospital appointments in Cambridge he continued his clinical research at Hammersmith Hospital before being appointed to the Chair in Clinical Biochemistry at Newcastle University and heading the joint University-NHS Department. He remains very active in research in areas such as the development of next generation high performance diagnostic systems and, in therapeutics, the development of technology that allows antibodies to be made light dependent such that they are active only in those regions where they are required in the body.
Lord Turnberg of Cheadle
Leslie Turnberg was Professor of Medicine in the University of Manchester from 1973 to 1997, and consultant gastroenterologist at Hope Hospital, Salford. He was Dean of the Faculty of Medicine from 1986 to 1989, President of the Royal College of Physicians (1992 to 1997), Chairman of the Academy of Medical Royal Colleges (1994 to 1996) and Chairman of the Specialist Training Authority (1996 to 1998). He was President of the Medical Protection Society (1997 to 2007), he chaired the Board of the Public Health Laboratory Service (1997 to 2002), the UK Forum on Genetics and Insurance (1999 to 2002), the Health Quality Service (2000 to 2004), the Board of the National Centre for Replacement, Reduction and Refinement of Research in Animals (2004 to 2007) and the Medical Advisory Board of Nations Health Care (2004 to 2007). He was Vice President of the Academy of Medical Sciences (1998 to 2004) and chaired the panel set up to review the Health Services in London for the new Labour Government (1997). He served on the House of Lords Select Committee on Science and Technology (2001 to 2005) and currently is a non-executive member of a bio-tech company (Renovo). He acts as Scientific Advisor to the Association of Medical Research Charities and is a Trustee of The Wolfson Foundation, The Foulkes Foundation, Ovarian Cancer Action, DIPEX and a number of other charities. He was knighted in 1994 and raised to a Peerage in 2000.